Archives: 2022-12-31

PIER MARIA FORNASARI
2022-12-31

Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial with a 99% response rate

An innovative immunotherapy combination has shown a stunning 99% response rate in children with relapsed leukemia. The phase 2 trial, run jointly between researchers at St. Jude Children’s Research Hospital in Memphis and Shanghai Children’s Hospital in China tested the therapy in 225 children who had relapsed after conventional treatment. The work published in the Journal

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-12-30

China’s COVID-19 wave forecast to have two peaks where cases could reach 4.2 million a day: ew modelling by Airfinity examining data from China’s regional provinces

China is predicted to see two peaks in cases as COVID-19 spreads throughout the country, the first peak in mid-January and the second in early March.  New modelling by Airfinity has examined data from China’s regional provinces. The current outbreak is growing more rapidly in some regions than in others. Cases are currently rising much

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-12-29

Two synthetic biology experiments offer hope for future cancer treatments with CAR-T cells

New immunotherapies can allow healing cells to be activated or deactivated according to the stage of the disease, while more accurately targeting tumors While CAR T therapy represents one of the most impressive innovations in cancer care, the treatment can cause autoimmune-like side effects. Many have contended with the dilemma of maximizing the therapy’s benefits

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-12-29

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

 Pfizer announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B. The BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post-fidanacogene elaparvovec infusion

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2022-12-28

Researchers of Tel Aviv University use Smartwatches to Measure Safety of COVID Vaccine

Tel Aviv University researchers monitored the physiological data of close to 5,000 Israelis over two years In a first-of-its-kind study, researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years. Of those monitored, 2,038 received the booster dose of the coronavirus vaccine, allowing the researchers

Read More

No Comments InUncategorized
PIER MARIA FORNASARI
2022-12-28

Mapping the hurdles for the clinical applications of ATMPs and Clinical trials of combined ATMPs: two forthcoming single-stage Horizon Europe framework programs

1) Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs) Deadline model single-stage Planned opening date 12 January 2023 Deadline date 13 April 2023 17:00:00 Brussels time ExpectedOutcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative,

Read More

No Comments InUncategorized
PIER MARIA FORNASARI
2022-12-28

Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases. An open Horizon Europe Framework Program for consortia.

Single stage with dead-line 15 march 2023 ExpectedOutcome: Research and innovation (R&I) actions to be supported under this topic must work towards results that contribute to all the following expected outcomes. Scope: There are over 7 000 rare diseases resulting in 30 million patients1 in Europe with a rare disease. Globally more than 300 million patients2 are

Read More

No Comments InUncategorized
PIER MARIA FORNASARI
2022-12-28

Wafer-thin device has potential to transform the field of islet cell transplantation

Implantable platform provides prolonged treatment of Type 1 diabetes A quarter-sized device created at Houston Methodist could drastically alter the course of treatment for Type 1 diabetes, a chronic condition that impacts millions of Americans and does not have a cure. In a study published in the Dec. 26 issue of Nature Communications, a research team led

Read More

No Comments InREGENERATIVE MEDICINE
PIER MARIA FORNASARI
2022-12-19

Global study presents first results on the longer-term effects of therapies for the treatment of critically ill patients with COVID-19

The world’s largest trial into the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes has released results from the 180-day (six month) follow-up of 4869 critically ill patients. Published today in The Journal of the American Medical Association (JAMA), the study is part of the ongoing Randomized Embedded Multifactorial Adaptive Platform

Read More

No Comments InCovid-19